At Uromigos Live 2024, a bladder cancer panel moderated by Dr. Tom Powles focused on the use of antibody drug conjugates for the treatment of bladder cancer, analyzing the response rates of various ADC treatments and their related side effects.
Dr. Powles was joined by Andrea Apolo, MD, of the National Institute of Health; Petros Grivas, MD, PhD, of the University of Washington; Shilpa Gupta, MD, of Cleveland Clinic; and Kala Sridhar, MD, of Princess Margaret Cancer Center.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape was discussed. The panelists also break down the EV-103 study and EV-302.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.